Figure 1
From: P2x7 deficiency suppresses development of experimental autoimmune encephalomyelitis
Effect of P2x7 deficiency on the development of clinical signs of EAE. P2x7 null and wildtype C57BL6 mice were immunized to develop EAE using MOG35–55 peptide, and clinical scores monitored approximately daily. Day 0 is defined as the day of the MOG peptide booster immunization. The data from 3 separate studies using P2x7 null mice (n = 38 total) and 2 separate studies using WT mice (n = 24 total) are combined. Data in (A) shows average incidence of disease (defined by at least 2 consecutive days with a score of 1.0 or greater). Data in (B) shows average clinical scores (mean ± se) for all mice. Data in (C) show average clinical scores (mean ± se) for only those mice that became ill (7/38 in the P2x7 null group; and 15/24 in the WT group).